ENGLEWOOD, Colo., Sept. 18, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) phase three clinical trial titled  "Evaluating the Efficacy and Safety of Ampion to treat Adults with Pain Due to Severe Osteoarthritis of the Knee", today announced 

KAPOLEI, Hawaii and TAMPA, Fla., Sept. 18, 2019 /PRNewswire/ -- WellCare Health Plans, Inc. (NYSE: WCG) ("WellCare") announced the WellCare Community Foundation donated $10,000 to support the Boys & Girls Club of the Big Island (B&GC) in Hilo, Hawaii. Big Island e

SOUTH PLAINFIELD, N.J., Sept. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it has priced its private offering of $250.0 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes"). The Notes will be sold only to qualified institutional buyers pursuant to Rule 144A under the

SOUTH PLAINFIELD, N.J., Sept. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today the pricing of a public offering of 2,475,248 shares of its common stock at a public offering price of $40.40 per share, before underwriting discounts and commissions. In addition, PTC has granted the underwriter an option for a

EMERYVILLE, Calif., Sept. 18, 2019 /PRNewswire/ -- Today Berkeley Lights, Inc. (BLI), the company dedicated to finding the best cell for any application, announced the appointme

SEATTLE, Sept. 18, 2019 /PRNewswire/ -- Sound Pharmaceuticals is pleased to announce that the FDA's Division of Neurology Products has granted its request for Fast Track Designation (FTD) involving SPI-1005 in the treatment of Meniere's Disease (MD). FTD applies to serious conditions where the potential to address unmet medical need has been demonstrated. SPI's clinical

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 /PRNewswire/ -- National Institutes of Health's National Institute on Drug Abuse (NIDA) has approved approximately $6.1 million in second-year funding for Titan's non-clinical development of a ProNeura™ based six-month implantable formulation of Nalmefene, an opioid antagonist, intended

MISGAV, Israel, Sept. 18, 2019 /PRNewswire/ -- OrthoSpin Ltd. a portfolio company of The Trendlines Group Ltd. ("Trendlines") (SGX: 42T) (OTCQX: TRNLY), announced today that it received regulatory clearance from the United States Food and Drug Administration (FDA) for its smart, robot

NEW YORK and CAESAREA, Israel, Sept. 18, 2019 /PRNewswire/ -- DarioHealth Corp. ("DarioHealth" or "Dario") (Nasdaq: DRIO), a leading, global digital therapeutics company, today announced that it has received a notice of allowance from the U.S. P

SAN DANIELE DEL FRIULI, Italy, Sept. 18, 2019 /PRNewswire/ -- LimaCorporate is pleased to announce that Rodrigo Bianchi will join the LimaCorporate Advisory Board.